RUS 350Alternative Names: RUS350
Latest Information Update: 01 Oct 2010
At a glance
- Originator Cambridge Laboratories
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 28 Sep 2010 Biovail Corporation merged with Valeant Pharmaceuticals International forming Valeant Pharmaceuticals International
- 22 May 2009 Phase-I clinical trials in Huntington's disease in United Kingdom (PO)